Alcidion Group Limited · ASX:ALC
Alcidion — FY2021 Earnings Presentation
16 slides from Alcidion's earnings presentation, Aug 24, 2021
Slide 1: Webinar Presentation FY21 Full Year Results
For personal use only Webinar Presentation FY21 Full Year Results 24 August 2021 1
Slide 2: Making the right thing to do, the easiest thing to do
Alcidion helps healthcare organisations harness the power of technology to create a clinically For personal use only relevant environment with digitally enabled care… “Making the right thing to do, the easiest thing to do” 2
Slide 3: FY21 – Financial Summary
FY21 – Financial Summary For personal use only Strong growth in all key financial metrics and record sold revenue heading into FY22 Revenue $25.9m 39% 1 Recurring Revenue $16.3m 56% 88.3% Improvement $15.1m 2.4pts Gross Sold Revenue For FY22 18% Margin on FY20 (85.9%) $0.5m Underlying EBITDA (Loss)
Slide 4: FY21 – Contracts Summary
FY21 – Contracts Summary For personal use only Milestone contracts across all three geographical regions; focus now on accelerating contract wins • South Tees NHS Hospitals: (incl extension) 2nd Miya Precision deployment in UK United • NHSX Clinical Communications Procurement Framework: Smartpage in
Slide 5: FY21 – Corporate Summary
FY21 – Corporate Summary For personal use only Executed key operational and corporate strategies which underpin future growth profile • In April 2021, acquired ExtraMed, a leading UK provider of patient flow management software ExtraMed • 9 NHS Trusts, 6 new for Alcidion; increasing number of NHS Tr
Slide 6: FY21 - Financial Dashboard
FY21 - Financial Dashboard For personal use only Revenue Revenue by region FY19 FY20 FY21 H1 $25.9M H2 14.8 $18.6M 16% 22% $16.9M 39% 44% $25.9M 10% 10.4 $18.6M 56% 9.6 $16.9M 11.1 84% 78% 7.3 8.2 ANZ UK FY19 FY20 FY21 EBITDA ($0.0M) FY19 FY19 FY20 FY21 ($0.5M) ($3.8M) 6
Slide 7: Profit & Loss
Profit & Loss For personal use only Profit & Loss ($000) FY21 FY20 % Change Key Comments Recurring 16,343 10,458 56% Non-recurring 9,539 8,150 17% • Record FY21 revenue of $25.9m, up 39% on FY20 ($18.6m) Total Revenue 25,882 18,608 39% Cost of Sales (3,018) (2,621) (15%) − Recurring revenue of $16.3
Slide 8: Balance Sheet
Balance Sheet For personal use only Balance Sheet ($000) FY21 FY20 % Change Key Comments Cash & equivalents 25,027 15,948 57% Trade and other receivables 4,114 3,833 7% • Strong balance sheet with $25.0m cash and no debt Other assets - prepayments 1,206 445 171% Current Assets 30,347 20,226 50% – Ra
Slide 9: Cash Flow
Cash Flow For personal use only Cash Flows ($000) FY21 FY20 % Change Key Comments Receipts from customers 32,046 20,543 56% Payments to suppliers & employees (30,510) (22,630) 35% • Record $32.0m receipts from customers, an $11.5m (56%) increase Interest received 12 74 (84%) on FY20 Finance costs (3
Slide 10: Personnel
Personnel For personal use only Core team largely in place to deliver on growth strategy, albeit COVID has slowed hiring in some areas • Appointed Matthew Gepp as CFO, effective from June 2021, as part of planned growth objectives • Lynette Ousby promoted to the role of UK Managing Director Leadersh
Slide 11: UK NHSX – Acceleration of the Digital Strategy
UK NHSX – Acceleration of the Digital Strategy For personal use only Core Pillars of the Digital Strategy (EPR Strategy) • NHSX: joint unit of NHS England and the Department of Health and Social Care, supporting local NHS and care organisations to: Openness Ability to integrate with other platforms
Slide 12: ANZ – Favourable changing landscapes
ANZ – Favourable changing landscapes For personal use only Australia New Zealand Virtual Care & Remote Monitoring Centralising Health Decisions and Spending • Heightened focus (expedited by COVID) on virtual care & remote • NZ Government will consolidate all 20 District Health Boards monitoring driv
Slide 13: FY22 – Starting with a strong recurring base
FY22 – Starting with a strong recurring base For personal use only Key Comments • $15.1M of contracted revenue to be recognised in FY22, 18% Contracted Revenue (To be recognised in same year) higher than at similar time last year $26.0m • Further $2.9M of scheduled renewal revenue (existing customer
Slide 14: Growth Focus in FY22
Growth Focus in FY22 For personal use only Accelerating sales across all regions in line with strategy to become a global leader in healthcare technology 1 All Markets: Upsell Miya Precision (or other modules) to existing Alcidion customers 2 All: Win new Miya Precision installs 3 UK: Listed on Proc
Slide 15: Disclaimer
Disclaimer For personal use only The information contained in this document (“Document”) has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as “Alcidion” or “Company”). This Document is current as at the date of this Document and should be read in conjunction with other Alcidio
Slide 16: For personal use only
For personal use only